Moderation effect of the eveningness chronotype on the relationship between ADHD tendency and Internet addiction

Abstract

CYP1A2 enzymes, lowering the expected plasma levels of certain antipsychotics. 8 Therefore, asenapine add-on treatment might improve schizophrenia symptoms in individuals who had smoked in the previous 6 months. The RTS subgroup that included individuals with initial PANSS-P ≥ 20 (n = 17) had a more significant reduction in PANSS-P at the endpoint than the subgroup that included individuals with initial PANSS-P < 20 (Table S3). Other associations between some clinical factors and PANSS scores (Table S3) might not be robust because of the differences in patient numbers in each subgroup. However, discontinuation rates in both groups were similar (Table S4). Reported adverse events with a frequency of 10% or more in any groups included using an anticholinergic agent, oral paresthesia, somnolence, and weight gain (Table S5). The incidence of most adverse events in both groups was similar. However, the TRS group had 10% more individuals with weight gain than the RTS group. The recent meta-analyses demonstrated that the risk of weight gain was not pronounced in asenapine compared with other antipsychotics such as olanzapine and zotepine. 2,3 Although we cannot classify participants by the type of antipsychotic medication they were taking other than asenapine, differences in concomitant antipsychotics might influence this result.This post-hoc analysis demonstrated that asenapine add-on treatment might benefit individuals with TRS or RTS. Antipsychotic polypharmacy is frequent in clinical practice, despite the concern regarding the possibility of increased adverse effects and healthcare costs of antipsychotic polypharmacy. 9 The physicians would need to keep an eye on those patients' health. As asenapine treatment reduced only about five points of PANSS-T for both individuals, its clinical significance might be poor for some individuals who might be better off using clozapine.

Temporal patterns of sleep latency in central hypersomnia and attention deficit hyperactivity disorder: a cluster analysis exploration using Multiple Sleep Latency Test

“…While the distinctions between NT1, NT2, and IH remain pivotal, the intricate relationship between EDS and psychiatric disorders, particularly attention deficit hyperactivity disorder (ADHD), adds another layer of complexity (9). Recent studies have shown a strong coexistence between EDS and ADHD (10)(11)(12). For example, 61% of the patients with central hypersomnia with EDS exhibit ADHD-like symptoms (13), whereas 38% of individuals with ADHD have EDS (10).…”